Trial
NCT06516510
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Early Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Blue Earth Therapeutics Ltd
Collaborators
Medpace, Inc.
Condition
Metastatic Prostate Cancer
Intervention
lutetium (177Lu) rhPSMA 10.1 and Pluvicto®
Why stopped
Based on data from the Interim Analysis, the study will not adequately inform the clinical development programme for Lutetium (177Lu) rhPSMA-10.1 injection in the way that the study was intended. There are no concerns regarding participant safety.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-25